Humacyte (HUMA) just shared new two-year results from its V007 Phase 3 study at Kidney Week 2025. The ATEV device performed better than traditional AV fistulas for hemodialysis access, particularly in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback